Galapagos NV

Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board

26 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

24 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

18 Mar 2022 17:01:00 By Nasdaq GlobeNewswire

Galapagos 2021 results set stage for future growth

24 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos receives transparency notification from EcoR1 Capital

03 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress

02 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plan

26 Jan 2022 16:40:00 By Nasdaq GlobeNewswire

Galapagos appoints Paul Stoffels as Chief Executive Officer

26 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN    

18 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plan

13 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 09:30:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

03 Dec 2021 16:01:00 By Nasdaq GlobeNewswire

Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

22 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis

15 Nov 2021 10:45:07 By Nasdaq GlobeNewswire

Galapagos reports commercial and operational progress at Q3 financial results

04 Nov 2021 17:01:00 By Nasdaq GlobeNewswire

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

04 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

04 Oct 2021 01:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

20 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

17 Sep 2021 07:15:00 By Nasdaq GlobeNewswire

Galapagos announces planned retirement of CEO

30 Aug 2021 16:01:00 By Nasdaq GlobeNewswire